Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world
Anselm K. Gitt,
Dominik Lautsch,
Jean Ferrières,
Gaetano M. De Ferrari,
Ami Vyas,
Carl A. Baxter,
Lori D. Bash,
Veronica Ashton,
Martin Horack,
Wael Almahmeed,
Fu-Tien Chiang,
Kian Keong Poh,
Philippe Brudi,
Baishali Ambegaonkar
Affiliations
Anselm K. Gitt
Herzzentrum Ludwigshafen, Germany; Institut für Herzinfarktforschung Ludwigshafen, Germany; Correspondence to: Herzzentrum Ludwigshafen, Med. Klinik B, Cardiology Department and Stiftung “Institut für Herzinfarktforschung”, Bremser Strasse 79, 67063 Ludwigshafen, Germany. Fax: 49 621 5034165.
Dominik Lautsch
Merck & Co., Inc., Kenilworth, NJ, USA
Jean Ferrières
Rangueil Hospital, Toulouse University School of Medicine, Toulouse, France
Gaetano M. De Ferrari
Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
Ami Vyas
Rutgers University, School of Public Health, Piscataway, NJ, USA
Carl A. Baxter
MSD Ltd. Hoddesdon, UK
Lori D. Bash
Merck & Co., Inc., Kenilworth, NJ, USA
Veronica Ashton
Agile-1 for Merck & Co., Inc., Kenilworth, NJ, USA
Martin Horack
Institut für Herzinfarktforschung Ludwigshafen, Germany
Wael Almahmeed
Sheikh Khalifa Medical City, Abu Dhabi, UAE; Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, UAE
Fu-Tien Chiang
National Taiwan University Hospital, Taipei, Taiwan and Fu-Jen Catholic University Hospital, Taipei, Taiwan
Kian Keong Poh
Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Cardiology, National University Heart Center Singapore, National University Health System, Singapore
DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8% receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9% of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32% of all patients received laboratory lipid testing. 37% attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied. Conclusions: Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event. Keywords: Low-density lipoprotein cholesterol, Treatment target, Global, Region, Statins